What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Nucleotides are the monomeric units of nucleic acids and serve as activated intermediates in numerous metabolic pathways. Each nucleotide consists of a nitrogenous base, a five-carbon sugar (ribose or deoxyribose), and one or more phosphate groups. The formation of nucleotides occurs through two principal routes: de novo biosynthesis, in which the heterocyclic ring is assembled from small precursors, and salvage pathways, which recycle preformed bases and nucleosides derived from dietary sources or nucleic acid turnover. Understanding nucleotide formation is essential for grasping how cells maintain the pools of building blocks required for DNA replication, transcription, and signal transduction.

Introduction to Nucleotide Formation

Components of a Nucleotide

A nucleotide is composed of three covalently linked moieties. The nitrogenous base is a heterocyclic aromatic ring containing nitrogen atoms. Two families exist: purines (adenine and guanine), which feature a fused six-membered and five-membered ring system, and pyrimidines (cytosine, thymine, and uracil), which contain a single six-membered ring. The sugar is either D-ribose (in RNA nucleotides) or 2-deoxy-D-ribose (in DNA nucleotides), attached to the base via a β-N-glycosidic bond between the anomeric carbon (C1′) of the sugar and N9 of a purine or N1 of a pyrimidine. The phosphate group is esterified to the C5′ hydroxyl of the sugar. Nucleosides lack the phosphate group; nucleotides are therefore nucleoside phosphates. For a detailed structural treatment, see Nucleotide Structure and Nucleotide Nucleoside.

Biological Importance

Nucleotide formation is not merely a prerequisite for nucleic acid synthesis. Nucleotides function as energy carriers (ATP, GTP), as components of coenzymes (NAD⁺, FAD, coenzyme A), and as intracellular signaling molecules (cAMP, cGMP). The de novo pathways consume significant metabolic resources—approximately 6 ATP equivalents per purine nucleotide synthesized—and are therefore tightly regulated. Cells also maintain balanced pools of all four deoxyribonucleoside triphosphates (dNTPs); imbalances increase mutation rates during DNA replication. Defects in nucleotide metabolism underlie severe human diseases, including immunodeficiency, orotic aciduria, and Lesch-Nyhan syndrome.

De Novo Purine Biosynthesis Pathway

Unlike pyrimidine synthesis, in which the ring is assembled before attachment to ribose, purine nucleotides are built directly onto a ribose-phosphate scaffold. The committed step is the formation of phosphoribosyl pyrophosphate (PRPP), followed by a sequence of ten enzymatic reactions that convert PRPP to inosine monophosphate (IMP), the common precursor of AMP and GMP.

Formation of PRPP

PRPP is synthesized from ribose-5-phosphate and ATP by ribose-phosphate pyrophosphokinase (PRPP synthetase, encoded by PRPS1 in humans). The reaction transfers the β,γ-pyrophosphate moiety of ATP to the C1 hydroxyl of ribose-5-phosphate, yielding PRPP and AMP.

Ribose-5-phosphate + ATP → PRPP + AMP

PRPP synthetase is allosterically activated by inorganic phosphate and inhibited by purine nucleotides (ADP and GDP). PRPP occupies a central position in nucleotide metabolism: it is the donor of the phosphoribosyl group not only in de novo purine synthesis but also in pyrimidine nucleotide synthesis and in salvage reactions. The intracellular concentration of PRPP is normally low (approximately 5–10 µM in resting cells), and its availability is rate-limiting for purine synthesis.

Assembly of the Purine Ring

The purine ring is assembled stepwise on the ribose-phosphate backbone. The pathway proceeds through the following reactions, each catalyzed by a distinct enzyme:

**Amidophosphoribosyltransferase (ATase, PPAT)** replaces the pyrophosphate of PRPP with the amide nitrogen of glutamine, forming 5-phosphoribosylamine (PRA). This is the committed step of purine synthesis and is feedback-inhibited by AMP and GMP.
**GAR synthetase (GART)** adds glycine to PRA using ATP, forming glycinamide ribonucleotide (GAR).
GAR transformylase transfers a formyl group from N¹⁰-formyltetrahydrofolate to the amino group of GAR, yielding formylglycinamide ribonucleotide (FGAR).
**FGAM synthetase (PFAS)** catalyzes ATP-dependent amidation of FGAR using glutamine as the nitrogen donor, producing formylglycinamidine ribonucleotide (FGAM).
**AIR synthetase (GART)** closes the imidazole ring of the purine skeleton via ATP-dependent dehydration, forming 5-aminoimidazole ribonucleotide (AIR).
**CAIR synthetase (PAICS)** carboxylates AIR at C4 using bicarbonate and ATP, yielding carboxyaminoimidazole ribonucleotide (CAIR).
**SAICAR synthetase (PAICS)** condenses CAIR with aspartate, forming succinylaminoimidazole carboxamide ribonucleotide (SAICAR).
**adenylosuccinate lyase (ADSL)** eliminates fumarate from SAICAR, producing aminoimidazole carboxamide ribonucleotide (AICAR).
**AICAR transformylase (ATIC)** transfers a second formyl group from N¹⁰-formyltetrahydrofolate, yielding formylaminoimidazole carboxamide ribonucleotide (FAICAR).
**IMP cyclohydrolase (ATIC)** dehydrates FAICAR to close the six-membered ring, producing inosine monophosphate (IMP).

The pathway consumes 5 ATP equivalents and 2 molecules of tetrahydrofolate-derived formyl groups per IMP synthesized. Notably, the bifunctional enzymes GART (steps 2, 5) and ATIC (steps 9, 10) in higher eukaryotes reduce the number of distinct polypeptides required.

Conversion of IMP to AMP and GMP

IMP is a branch point. It is converted to AMP by two reactions:

**Adenylosuccinate synthetase (ADSS)** condenses IMP with aspartate and GTP, forming adenylosuccinate.
Adenylosuccinate lyase removes fumarate, yielding AMP.

Conversion of IMP to GMP also requires two steps:

**IMP dehydrogenase (IMPDH)** oxidizes IMP to xanthosine monophosphate (XMP) using NAD⁺ as the electron acceptor.
**GMP synthetase (GMPS)** aminates XMP at C2 using glutamine and ATP, producing GMP.

The pathways are reciprocally regulated: GTP is required for AMP synthesis, and ATP is required for GMP synthesis. This arrangement helps balance the adenine and guanine nucleotide pools.

De Novo Pyrimidine Biosynthesis Pathway

Pyrimidine synthesis differs fundamentally from purine synthesis: the pyrimidine ring is assembled first as a free molecule (orotic acid) and then attached to ribose-5-phosphate. The pathway is cytosolic in animals, with the first three enzymatic activities residing on a single multifunctional polypeptide, CAD (carbamoyl phosphate synthetase II, aspartate transcarbamoylase, dihydroorotase).

Carbamoyl Phosphate Synthesis

Carbamoyl phosphate is synthesized from glutamine, bicarbonate, and two molecules of ATP by carbamoyl phosphate synthetase II (CPS II), the glutamine-dependent isoform found in the cytosol. This is distinct from carbamoyl phosphate synthetase I, a mitochondrial enzyme that uses ammonia and participates in the urea cycle. CPS II is the rate-limiting step of pyrimidine synthesis and is allosterically inhibited by UTP and activated by PRPP.

Formation of Orotic Acid

The subsequent reactions assemble the pyrimidine ring:

Aspartate transcarbamoylase (ATCase) condenses carbamoyl phosphate with aspartate, forming N-carbamoylaspartate. In bacteria, ATCase is a separate enzyme subject to feedback inhibition by CTP; in animals, it is part of the CAD polypeptide.
Dihydroorotase cyclizes N-carbamoylaspartate by removing water, forming dihydroorotate.
Dihydroorotate dehydrogenase (DHODH) oxidizes dihydroorotate to orotate. In animals, this enzyme is located on the outer surface of the inner mitochondrial membrane and uses ubiquinone (coenzyme Q) as the electron acceptor. This mitochondrial localization is clinically significant: the immunosuppressive drug leflunomide inhibits DHODH.

Decarboxylation to UMP

Orotate is converted to uridine monophosphate (UMP) in two steps catalyzed by the bifunctional enzyme UMP synthase (encoded by UMPS in humans):

Orotate phosphoribosyltransferase (OPRT) transfers the phosphoribosyl group from PRPP to orotate, forming orotidine monophosphate (OMP).
OMP decarboxylase (OMPDC) decarboxylates OMP to yield UMP.

This is the only step in pyrimidine synthesis that uses PRPP. OMPDC is one of the most catalytically efficient enzymes known, with a rate enhancement of roughly 10¹⁷-fold over the uncatalyzed reaction. Inherited deficiency of UMP synthase causes orotic aciduria, characterized by megaloblastic anemia, orotic acid crystalluria, and failure to thrive; treatment with oral uridine bypasses the block.

Synthesis of CTP and dTMP

UMP is phosphorylated to UDP and UTP by nucleoside monophosphate kinase and nucleoside diphosphate kinase, respectively. **CTP synthetase (CTPS)** then aminates UTP at C4 using glutamine and ATP, producing CTP. This reaction is allosterically activated by GTP and inhibited by CTP.

Thymidylate (dTMP) synthesis requires deoxyuridine monophosphate (dUMP) as substrate. The conversion of dUMP to dTMP is catalyzed by thymidylate synthase (TYMS), which transfers a methylene group from N⁵,N¹⁰-methylene-tetrahydrofolate to dUMP while simultaneously reducing the folate cofactor to dihydrofolate (DHF). This reaction is the sole de novo source of thymidylate and is a major target of anticancer drugs, including 5-fluorouracil, which forms a covalent inhibitory complex with thymidylate synthase. The DHF produced must be reduced back to tetrahydrofolate by dihydrofolate reductase (DHFR), the target of methotrexate.

Salvage Pathways for Nucleotide Formation

De novo synthesis is energetically expensive. Many cells, particularly erythrocytes (which lack mitochondria and cannot perform de novo purine synthesis) and brain tissue, rely heavily on salvage pathways that recycle free bases and nucleosides.

Purine Salvage

Two key enzymes mediate purine salvage:

**Hypoxanthine-guanine phosphoribosyltransferase (HGPRT, encoded by HPRT1)** transfers the phosphoribosyl group from PRPP to hypoxanthine or guanine, forming IMP or GMP, respectively.
Adenine phosphoribosyltransferase (APRT) performs the analogous reaction with adenine, producing AMP.

Both enzymes are constitutively expressed and have high affinity for their substrates (Km values in the low micromolar range). The PRPP consumed in salvage reactions is the same pool used for de novo synthesis, so salvage and de novo pathways compete for this substrate.

Pyrimidine Salvage

Pyrimidine salvage is less critical than purine salvage because cells can synthesize pyrimidines more readily. The primary enzyme is uridine-cytidine kinase, which phosphorylates uridine and cytidine to their monophosphates using ATP. Thymidine kinase (TK1, cytosolic; TK2, mitochondrial) phosphorylates thymidine to dTMP and is induced during S phase of the cell cycle. Free pyrimidine bases (uracil, thymine) are less efficiently salvaged; uracil phosphoribosyltransferase activity is present in some tissues but is not a major route in humans.

Clinical Relevance (e.g., Lesch-Nyhan syndrome)

Complete deficiency of HGPRT causes Lesch-Nyhan syndrome, an X-linked recessive disorder characterized by hyperuricemia, gout-like arthritis, kidney stones, self-injurious behavior, and intellectual disability. The pathophysiology is instructive: without HGPRT, hypoxanthine and guanine cannot be recycled, so PRPP accumulates and drives excessive de novo purine synthesis. The resulting overproduction of uric acid (the final catabolite of purines) causes the clinical manifestations. The neurological symptoms are less well understood but likely reflect the dependence of dopaminergic neurons on guanine nucleotide salvage for normal function. Partial HGPRT deficiency causes Kelley-Seegmiller syndrome, with hyperuricemia but without neurological involvement.

Formation of Deoxyribonucleotides

DNA synthesis requires deoxyribonucleoside triphosphates (dNTPs), which are produced by reduction of the 2′-hydroxyl group of ribonucleotides. This reaction is catalyzed by ribonucleotide reductase (RNR), an enzyme that is essential in all organisms capable of DNA replication.

Ribonucleotide Reductase Mechanism

RNR reduces the 2′-OH of a ribonucleoside diphosphate (NDP) to a hydrogen, producing the corresponding deoxyribonucleoside diphosphate (dNDP). The reaction requires a reducing equivalent, which is supplied by thioredoxin or glutaredoxin:

The NDP substrate binds to the active site of RNR.
A cysteine pair in the enzyme active site reduces the 2′-OH, generating water and a disulfide bond in the enzyme.
The disulfide is reduced by thioredoxin (which itself becomes oxidized).
Thioredoxin reductase regenerates reduced thioredoxin using NADPH.

The class Ia RNR found in mammals is an α₂β₂ tetramer. The α subunit (RRM1) contains the catalytic and allosteric regulatory sites; the β subunit (RRM2) contains a stable tyrosyl radical generated by a di-iron center, which is essential for catalysis. The radical is transferred to the active site cysteine to initiate the reduction. Because the tyrosyl radical is oxygen-sensitive, RNR activity is highest in S phase, when RRM2 expression is induced.

Regulation of dNTP Pools

RNR is subject to complex allosteric regulation that ensures balanced dNTP pools. Two classes of allosteric sites exist on the α subunit:

Activity site (A-site): Binding of ATP activates the enzyme; binding of dATP inhibits it. This ensures that RNR is active only when the cell has sufficient energy charge.
Specificity site (S-site): Binding of different nucleotides shifts substrate preference. ATP or dATP favors reduction of CDP and UDP; dTTP favors GDP reduction; dGTP favors ADP reduction.

This pattern ensures that as the concentration of one dNTP rises, it redirects RNR activity toward producing the other dNTPs, maintaining a balanced pool. Imbalances in dNTP pools increase mutation rates and can cause replication stress, contributing to genomic instability.

Regulation of Nucleotide Biosynthesis

Nucleotide pools must be maintained within narrow ranges: too little limits DNA replication and repair; too much promotes mutagenesis. Regulation occurs primarily at the level of allosteric feedback inhibition of committed steps, with additional transcriptional control in proliferating cells.

Feedback Inhibition in Purine Synthesis

The two regulatory nodes in purine synthesis are:

PRPP synthetase: Inhibited by ADP and GDP, preventing excessive PRPP production when purine nucleotides are abundant.
Amidophosphoribosyltransferase (ATase): Inhibited by AMP and GMP (the end products) and activated by PRPP. This is the committed step and the primary site of feedback control.

Additionally, IMP dehydrogenase (IMP → XMP) is inhibited by GMP, and adenylosuccinate synthetase (IMP → adenylosuccinate) is inhibited by AMP. This allows the branch pathways to respond independently to the relative needs for adenine versus guanine nucleotides.

Regulation of Pyrimidine Synthesis

In bacteria, the committed step is catalyzed by ATCase, which is strongly inhibited by CTP (the end product) and activated by ATP. In mammals, the equivalent control is exerted on CPS II within the CAD polypeptide: UTP inhibits, and PRPP activates. This difference is clinically relevant: the bacterial enzyme is a classic model for allosteric regulation, but therapeutic targeting of pyrimidine synthesis in humans focuses on CPS II or downstream enzymes such as DHODH.

Cross-Pathway Regulation

Purine and pyrimidine pathways are interconnected through PRPP and through nucleotide interconversions. For example, high concentrations of purine nucleotides inhibit PRPP synthetase, reducing PRPP availability for pyrimidine synthesis. Conversely, UTP inhibits CPS II, and CTP synthetase is activated by GTP, linking pyrimidine synthesis to purine availability. These cross-regulatory interactions ensure that the total nucleotide pool expands and contracts in a coordinated manner during cell growth.

Experimental Methods to Study Nucleotide Formation

Investigating nucleotide biosynthesis requires methods to trace metabolic flux, measure enzyme activity, and perturb pathway components.

Radiolabeled Precursor Tracing

Classic studies used radiolabeled precursors to map biosynthetic pathways. For example, feeding cells [¹⁴C]formate or [¹⁴C]glycine and analyzing the position of the label in the purine ring established the origin of each ring atom. Similarly, [³H]orotate is used to measure de novo pyrimidine synthesis: incorporation of tritium into UMP and downstream nucleotides reflects flux through the pathway. Modern approaches use stable isotopes (¹³C, ¹⁵N) with mass spectrometry to quantify fluxes through individual reactions.

Enzyme Activity Assays

Enzyme activities are measured using spectrophotometric or radiochemical assays. For example, ATase activity is assayed by measuring the production of 5-phosphoribosylamine from PRPP and glutamine, typically using a coupled assay that detects glutamate release. Ribonucleotide reductase activity is measured by following the reduction of [³H]CDP to [³H]dCDP, with separation of substrate and product by thin-layer chromatography. Assays are performed at 37°C in buffers containing 50 mM HEPES (pH 7.2), 5 mM MgCl₂, and 1 mM dithiothreitol to maintain reducing conditions.

Mutant Studies

Genetic approaches have been invaluable. In bacteria, auxotrophic mutants requiring exogenous purines or pyrimidines for growth identified the genes encoding biosynthetic enzymes. In humans, naturally occurring mutations—such as HPRT1 in Lesch-Nyhan syndrome or UMPS in orotic aciduria—reveal the physiological roles of these enzymes. More recently, CRISPR-Cas9-mediated knockout of biosynthetic genes in cultured cells has allowed systematic analysis of pathway requirements under different growth conditions.

Common Pitfalls and Misconceptions in Nucleotide Formation

Distinguishing Purine vs. Pyrimidine Synthesis

Students frequently confuse the order of ring assembly. In purine synthesis, the ring is built on the ribose-phosphate (PRPP) scaffold; there is no free purine base intermediate. In pyrimidine synthesis, the ring is assembled first (as orotate) and then attached to ribose via PRPP. A useful mnemonic: purines are "built on the sugar," pyrimidines are "built first, attached later."

Role of PRPP

PRPP is not merely an activated ribose donor; it is a branch point metabolite whose concentration controls flux into both purine and pyrimidine pathways. Students often overlook that PRPP is consumed in salvage reactions as well as de novo synthesis, and that its overproduction (as in HGPRT deficiency) drives excessive purine synthesis.

Regulation vs. Inhibition

Feedback inhibition is not the same as transcriptional regulation. Allosteric inhibition acts within seconds to minutes and modulates existing enzyme activity; transcriptional regulation (e.g., induction of RRM2 or TYMS in S phase) changes enzyme amounts over hours. Both are required for proper nucleotide pool homeostasis, but they operate on different timescales.

Overlooking the Folate Connection

Purine synthesis requires two formyl transfers from tetrahydrofolate, and dTMP synthesis requires methylene-tetrahydrofolate. Drugs that inhibit folate metabolism (methotrexate, sulfonamides) therefore impair nucleotide synthesis indirectly. Students often memorize the folate requirement but fail to connect it to the specific reactions.

Assuming All Cells Synthesize Nucleotides De Novo

Many differentiated cells, including erythrocytes and neurons, have limited or absent de novo synthesis and depend on salvage pathways. This explains the tissue-specific toxicity of certain drugs (e.g., methotrexate affects rapidly dividing cells) and the neurological phenotype of Lesch-Nyhan syndrome.

Frequently Asked Questions

What are the steps of nucleotide formation?

Nucleotide formation occurs via two routes. De novo purine synthesis builds the purine ring on PRPP in ten steps to produce IMP, which is then converted to AMP or GMP. De novo pyrimidine synthesis assembles the pyrimidine ring as orotate, attaches it to ribose via PRPP, and decarboxylates to yield UMP; UMP is then converted to CTP and dTMP. Salvage pathways recycle free bases using PRPP. Deoxyribonucleotides are formed by reduction of ribonucleotides by ribonucleotide reductase.

What is the nucleotide formation process?

The nucleotide formation process encompasses all biochemical reactions that produce nucleotides, including de novo synthesis from small precursors (glutamine, glycine, aspartate, bicarbonate, formate), salvage of preformed bases and nucleosides, and the reduction of ribonucleotides to deoxyribonucleotides. The process is regulated by feedback inhibition and allosteric control to maintain balanced nucleotide pools.

What is the mechanism of nucleotide formation?

The mechanism depends on the pathway. Purine synthesis proceeds by sequential addition of atoms to PRPP, with amide nitrogen from glutamine, glycine, formyl groups from tetrahydrofolate, and amino nitrogen from aspartate. Pyrimidine synthesis begins with carbamoyl phosphate and aspartate, forming orotate, which is then phosphoribosylated by PRPP. Ribonucleotide reductase reduces the 2′-OH of NDPs using a tyrosyl radical and thioredoxin as the reducing agent.

How are purine nucleotides formed?

Purine nucleotides are formed de novo by the stepwise assembly of the purine ring on PRPP, producing IMP. IMP is then converted to AMP (via adenylosuccinate) or GMP (via XMP). Purines can also be salvaged from free bases by HGPRT (hypoxanthine, guanine) or APRT (adenine).

How are pyrimidine nucleotides formed?

Pyrimidine nucleotides are formed de novo by first synthesizing orotate from carbamoyl phosphate and aspartate, then attaching ribose-5-phosphate from PRPP to form OMP, and decarboxylating to UMP. UMP is phosphorylated to UTP, which is aminated to CTP. dTMP is synthesized from dUMP by thymidylate synthase using methylene-tetrahydrofolate.

What is the role of PRPP in nucleotide formation?

PRPP is the activated ribose-5-phosphate donor. It provides the phosphoribosyl moiety for the first committed step of purine synthesis (ATase reaction), for the conversion of orotate to OMP in pyrimidine synthesis, and for salvage reactions catalyzed by HGPRT and APRT. PRPP also allosterically activates CPS II and ATase, promoting nucleotide synthesis when it is abundant.

What are the common mistakes in understanding nucleotide formation?

Common mistakes include confusing the order of ring assembly in purine versus pyrimidine synthesis, underestimating the role of PRPP as a shared substrate, conflating allosteric inhibition with transcriptional regulation, overlooking the folate dependence of purine and dTMP synthesis, and assuming all cells rely on de novo synthesis when many depend on salvage.

Key Takeaways

Nucleotides are formed by de novo synthesis (from small precursors) and salvage pathways (recycling free bases), with PRPP as a central activated ribose donor.
Purine synthesis builds the ring on PRPP in ten steps to yield IMP, the common precursor of AMP and GMP; the committed step is catalyzed by amidophosphoribosyltransferase.
Pyrimidine synthesis assembles the ring as orotate before attaching ribose; the committed step is carbamoyl phosphate synthetase II, and UMP is the first nucleotide produced.
Deoxyribonucleotides are generated by ribonucleotide reductase, which reduces NDPs to dNDPs using thioredoxin and is regulated by ATP (activator) and dATP (inhibitor) at the activity site.
Nucleotide biosynthesis is controlled by feedback inhibition at committed steps, with cross-regulation between purine and pyrimidine pathways ensuring balanced pools.
Salvage pathways are essential in tissues lacking de novo synthesis; HGPRT deficiency causes Lesch-Nyhan syndrome due to PRPP accumulation and purine overproduction.
Folate cofactors are required for purine synthesis (two formyl transfers) and dTMP synthesis, explaining the mechanism of antifolate drugs like methotrexate.